S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ESPR Esperion Therapeutics Inc

2.28

-0.04 (-1.72%)

28 Dec 2024 - Closed

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Esperion Therapeutics Charts.

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Esperion Therapeutics Charts.

Esperion Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 19 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 19 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 19 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 18 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Wednesday 18 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Wednesday 18 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 18 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 18 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 13 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Esperion Announces $210 Million Convertible Debt Financing
Friday 13 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Friday 13 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
Tuesday 3 December 2024 (4 weeks ago) • GlobeNewswire Inc.

More Esperion Therapeutics Inc News Articles

Vulcan Industries

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions